Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Max Healthcare Institute Ltd (MAXHEALTH.NS)
Gurugram, DL, IN
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including cardiac sciences, orthopedics, oncology, renal sciences, neurosciences, minimal access and general surgery, pulmonology, obstetrics, gynecology, pediatrics, and nephrology, liver and biliary sciences, gastroenterology and Gi surgery, plastic and reconstructive surgery, and organ transplants, as well as ear, nose, and throat. The company also provides Max@Home, a platform that offers health and wellness services at home; and MaxLab, which provides diagnostic services to patients outside its network of hospitals through various channels comprising third-party hospital laboratory management. It operates through a network of healthcare facilities, including hospitals and medical centres. The company was incorporated in 2001 and is based in Gurugram, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.69% | -8.55% | -0.55% | -10.45% | -14.51% | -4.89% | -15.34% | +84.00% | +329.72% | +789.44% | +789.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 7 | 0 |
| Buy | 13 | 0 |
| Hold | 3 | +1 |
| Sell | 1 | 0 |
| Strong Sell | 3 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+19.1% ★ Q1'26: +12.2% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+34.0% ★ Q1'26: +7.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+14.1% Q1'26: -1.9% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+22.8% ★ Q1'26: +24.8% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+12.2% ★ Q1'26: +11.6% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.1% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×1.48× Q1'26: 1.33× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 24 Rev. Ana. 25 EPS Ana. |
Mar 2027 26 Rev. Ana. 25 EPS Ana. |
Mar 2028 25 Rev. Ana. 25 EPS Ana. |
Mar 2029 12 Rev. Ana. 11 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
25.08B
est: 36.71B (-31.7%)
|
39.37B
est: 52.06B (-24.4%)
|
45.63B
est: 58.41B (-21.9%)
|
54.06B
est: 68.62B (-21.2%)
|
70.28B
est: 86.55B (-18.8%)
|
101.88B
85.75B – 105.96B
+17.7% YoY
|
120.81B
96.95B – 134.51B
+18.6% YoY
|
143.15B
114.21B – 165.50B
+18.5% YoY
|
167.64B
134.11B – 190.54B
+17.1% YoY
|
| EBITDA |
3.90B
est: 8.80B (-55.7%)
|
9.47B
est: 12.48B (-24.1%)
|
12.23B
est: 14.00B (-12.7%)
|
14.82B
est: 16.45B (-9.9%)
|
18.31B
est: 22.93B (-20.1%)
|
26.99B
22.72B – 28.07B
+17.7% YoY
|
32.00B
25.68B – 35.63B
+18.6% YoY
|
37.92B
30.26B – 43.84B
+18.5% YoY
|
44.41B
35.53B – 50.48B
+17.1% YoY
|
| EBIT |
2.43B
est: 7.10B (-65.8%)
|
7.58B
est: 10.07B (-24.7%)
|
10.24B
est: 11.30B (-9.4%)
|
12.75B
est: 13.27B (-3.9%)
|
15.28B
est: 19.01B (-19.7%)
|
22.38B
18.84B – 23.28B
+17.7% YoY
|
26.54B
21.30B – 29.55B
+18.6% YoY
|
31.45B
25.09B – 36.36B
+18.5% YoY
|
36.83B
29.46B – 41.86B
+17.1% YoY
|
| Net Income |
-1.38B
est: 505.25M (-372.2%)
|
6.05B
est: 8.77B (-31.0%)
|
11.04B
est: 12.15B (-9.2%)
|
10.58B
est: 12.88B (-17.9%)
|
10.76B
est: 14.36B (-25.1%)
|
16.65B
13.03B – 19.58B
+15.9% YoY
|
19.35B
15.42B – 22.51B
+16.2% YoY
|
23.51B
18.18B – 27.87B
+21.5% YoY
|
28.88B
21.37B – 34.00B
+22.8% YoY
|
| SGA |
6.39B
est: 7.93B (-19.4%)
|
9.53B
est: 11.24B (-15.3%)
|
9.86B
est: 12.62B (-21.8%)
|
11.17B
est: 15.50B (-27.9%)
|
14.75B
est: 18.85B (-21.8%)
|
22.19B
18.67B – 23.08B
+17.7% YoY
|
26.31B
21.11B – 29.29B
+18.6% YoY
|
31.17B
24.87B – 36.04B
+18.5% YoY
|
36.51B
29.21B – 41.49B
+17.1% YoY
|
| EPS |
-1.59
est: 0.52 (-407.5%)
|
6.25
est: 8.97 (-30.3%)
|
11.38
est: 12.43 (-8.5%)
|
10.89
est: 13.18 (-17.4%)
|
11.07
est: 14.69 (-24.6%)
|
17.03
13.32 – 20.03
+15.9% YoY
|
19.79
15.77 – 23.02
+16.2% YoY
|
24.04
18.59 – 28.51
+21.5% YoY
|
29.53
21.85 – 34.78
+22.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Abhay Soi | Executive Chairman & MD | 295M | male |
| Anas Abdul Wajid | Senior Director and Chief Sales & Marketing Officer | — | male |
| Anurag Krishna | Member of Group Medical Advisory Council & Chairman of Paediatrics & Paediatric Surgery | — | — |
| Colonel Harinder Singh Chehal | Senior Director & Chief Operating Officer - Cluster 2 | — | — |
| Dhiraj Aroraa | Senior Vice President, Company Secretary & Compliance Officer | — | male |
| Gagan Palta | General Counsel & Director | — | male |
| Prashant Singh | Director of Information Technology & Chief Information Officer | — | male |
| Sandeep Budhiraja | Member of Group Medical Advisory Council & Group Medical Director | — | — |
| Umesh Gupta | Member of Group Medical Advisory Council, Senior Director - HR & Chief People Officer | — | male |
| Yogesh Kumar Sareen | Senior Director & Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MAXHEALTH.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
